We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Şizofrenide İşlevsellik ve Paliperidon: Bireysel ve Toplumsal Performans Ölçeği ile Yapılan Çalığşmaların Gözden Geçirilmesi.
- Authors
Aydemir, Ömer
- Abstract
Even though the relief of symptoms can be achieved with the treatments used in schizophrenia, the re-gain of the functioning cannot be established to that extent. Patients can have difficulties in the social adaptation, impairment in interpersonal relations, problems in family communication, difficulties in occupational functioning, and inadequacy in self-care. Personal and Social Performance Scale (PSP) is a comprehensive and sensitive to change instrument developed for the assessment of social functioning in schizophrenia. Paliperidone provides significant remission in social functioning assessed with PSP. The pooled data of the three clinical trials with paliperidone are re-analyzed. In the analyses, paliperidone 3 mg provided an improvement of 8.3±17.1 in the PSP score, for 6 mg it is 9.0±14.8, for 9 mg 7.8±14.3, for 12 mg 9.5±15.0, and for 15 mg it is 12.2±15.7. With placebo, the reduction in the PSP score is 0.5±15.0. When the improvement of at least one category (i.e. one ten-point interval) is taken into consideration, 50.4% of the patients in the treatment of 3 mg of paliperidone, 56.1% in the 6 mg group, 49.6% in the 9 mg group, 54.1% in the 12 mg group and 63.6% in the 15 mg group achieved improvement. Patients in the paliperidone group improved significantly in social functioning when compared with patients in the placebo group. In acute schizophrenia with six-week treatment, paliperidone appears to be effective in the improvement of impairment in social functions.
- Subjects
PEOPLE with schizophrenia; INTERPERSONAL relations; HEALTH self-care; CLINICAL trials; PLACEBOS
- Publication
Klinik Psikofarmakoloji Bulteni, 2009, Vol 19, Issue Supp 2, p335
- ISSN
1017-7833
- Publication type
Article